Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
$6.22
+3.0%
$7.23
$4.59
$23.40
$276.13M0.731.17 million shs822,707 shs
iCo Therapeutics Inc. stock logo
ICOTF
iCo Therapeutics
$0.49
$0.37
$0.80
$1.82
$4.41M2.034,760 shs246 shs
Integrated BioPharma Inc. stock logo
INBP
Integrated BioPharma
$0.29
-1.4%
$0.29
$0.20
$0.42
$9M0.866,468 shs13,900 shs
Reliv' International, Inc. stock logo
RELV
Reliv' International
$2.52
$3.51
$2.50
$4.42
$4.40M-0.123,200 shsN/A
10 Best Stocks to Own: Fall 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
+2.98%-4.01%-21.86%-47.91%+41.04%
iCo Therapeutics Inc. stock logo
ICOTF
iCo Therapeutics
-1.68%+3.01%+13.67%+24.51%+25.06%
Integrated BioPharma Inc. stock logo
INBP
Integrated BioPharma
-1.38%-1.44%+7.66%-13.15%+24.71%
Reliv' International, Inc. stock logo
RELV
Reliv' International
0.00%0.00%-7.69%-16.28%-30.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
$6.22
+3.0%
$7.23
$4.59
$23.40
$276.13M0.731.17 million shs822,707 shs
iCo Therapeutics Inc. stock logo
ICOTF
iCo Therapeutics
$0.49
$0.37
$0.80
$1.82
$4.41M2.034,760 shs246 shs
Integrated BioPharma Inc. stock logo
INBP
Integrated BioPharma
$0.29
-1.4%
$0.29
$0.20
$0.42
$9M0.866,468 shs13,900 shs
Reliv' International, Inc. stock logo
RELV
Reliv' International
$2.52
$3.51
$2.50
$4.42
$4.40M-0.123,200 shsN/A
10 Best Stocks to Own: Fall 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
+2.98%-4.01%-21.86%-47.91%+41.04%
iCo Therapeutics Inc. stock logo
ICOTF
iCo Therapeutics
-1.68%+3.01%+13.67%+24.51%+25.06%
Integrated BioPharma Inc. stock logo
INBP
Integrated BioPharma
-1.38%-1.44%+7.66%-13.15%+24.71%
Reliv' International, Inc. stock logo
RELV
Reliv' International
0.00%0.00%-7.69%-16.28%-30.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
3.11
Buy$22.56262.63% Upside
iCo Therapeutics Inc. stock logo
ICOTF
iCo Therapeutics
0.00
N/AN/AN/A
Integrated BioPharma Inc. stock logo
INBP
Integrated BioPharma
0.00
N/AN/AN/A
Reliv' International, Inc. stock logo
RELV
Reliv' International
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest CAPR, ICOTF, INBP, and RELV Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/11/2025
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$24.00
7/14/2025
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
Alliance Global Partners
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
7/14/2025
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
Roth Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$31.00 ➝ $12.00
7/11/2025
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight$20.00
7/11/2025
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$77.00 ➝ $24.00
6/30/2025
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
Alliance Global Partners
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$20.00
6/26/2025
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
B. Riley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$21.00
6/25/2025
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
B. Riley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
6/25/2025
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
Jones Trading
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$40.00 ➝ $29.00
6/24/2025
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$77.00
(Data available from 9/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
$22.27M12.77N/AN/A$3.20 per share1.94
iCo Therapeutics Inc. stock logo
ICOTF
iCo Therapeutics
N/AN/AN/AN/A($0.07) per shareN/A
Integrated BioPharma Inc. stock logo
INBP
Integrated BioPharma
$50.32M0.18$0.04 per share6.56$0.64 per share0.45
Reliv' International, Inc. stock logo
RELV
Reliv' International
$35.06M0.13$0.06 per share44.53$6.36 per share0.40
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
-$40.47M-$1.64N/AN/AN/A-181.71%-62.71%-50.82%11/12/2025 (Estimated)
iCo Therapeutics Inc. stock logo
ICOTF
iCo Therapeutics
-$1.11M-$0.40N/AN/AN/AN/A-288.85%N/A
Integrated BioPharma Inc. stock logo
INBP
Integrated BioPharma
$110K$0.047.17N/A2.37%6.36%4.84%9/18/2025 (Estimated)
Reliv' International, Inc. stock logo
RELV
Reliv' International
-$440KN/AN/AN/A-0.61%-1.89%-1.31%N/A

Latest CAPR, ICOTF, INBP, and RELV Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/11/2025Q2 2025
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
-$0.48-$0.57-$0.09-$0.57$2.60 millionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
N/AN/AN/AN/AN/A
iCo Therapeutics Inc. stock logo
ICOTF
iCo Therapeutics
N/AN/AN/AN/AN/A
Integrated BioPharma Inc. stock logo
INBP
Integrated BioPharma
N/AN/AN/AN/AN/A
Reliv' International, Inc. stock logo
RELV
Reliv' International
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
N/A
4.37
4.37
iCo Therapeutics Inc. stock logo
ICOTF
iCo Therapeutics
N/A
0.72
0.72
Integrated BioPharma Inc. stock logo
INBP
Integrated BioPharma
N/A
3.72
1.70
Reliv' International, Inc. stock logo
RELV
Reliv' International
0.05
1.70
1.04

Institutional Ownership

CompanyInstitutional Ownership
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
21.68%
iCo Therapeutics Inc. stock logo
ICOTF
iCo Therapeutics
N/A
Integrated BioPharma Inc. stock logo
INBP
Integrated BioPharma
25.25%
Reliv' International, Inc. stock logo
RELV
Reliv' International
7.95%
CompanyEmployeesShares OutstandingFree FloatOptionable
Capricor Therapeutics, Inc. stock logo
CAPR
Capricor Therapeutics
10145.72 million40.92 millionOptionable
iCo Therapeutics Inc. stock logo
ICOTF
iCo Therapeutics
N/A9.05 millionN/ANot Optionable
Integrated BioPharma Inc. stock logo
INBP
Integrated BioPharma
15030.98 million10.16 millionNot Optionable
Reliv' International, Inc. stock logo
RELV
Reliv' International
911.75 millionN/ANot Optionable

Recent News About These Companies

RELV Reliv' International, Inc.
Reliv' International, Inc. (RELV)
Agape ATP Corporation (ATPC)
North American Morning Briefing: Stocks Set for -2-
India and Armenia: Emerging Geostrategic Synergy
Reliance Naval and Engineering Ltd
RELV Real-Time Quotes

New MarketBeat Followers Over Time

Media Sentiment Over Time

Capricor Therapeutics stock logo

Capricor Therapeutics NASDAQ:CAPR

$6.22 +0.18 (+2.98%)
Closing price 09/16/2025 04:00 PM Eastern
Extended Trading
$6.24 +0.02 (+0.24%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.

iCo Therapeutics stock logo

iCo Therapeutics OTCMKTS:ICOTF

Satellos Bioscience, Inc. is a regenerative medicine company, which engages in developing novel therapeutics. It operates through a proprietary technology platform, MyoReGenX™ and Leveraging MyoReGenX™, which identify stem cell based regeneration deficits in muscle diseases and develop therapeutic solutions. The company was founded by Frank Gleeson and Michael Rudnicki in 2018 and is headquartered in Toronto, Canada.

Integrated BioPharma stock logo

Integrated BioPharma OTCMKTS:INBP

$0.29 0.00 (-1.38%)
As of 09/16/2025 11:53 AM Eastern

Integrated BioPharma, Inc., together with its subsidiaries, manufactures, distributes, markets, and sells vitamins, nutritional supplements, and herbal products primarily in the United States and Luxembourg. It operates through Contract Manufacturing and Other Nutraceutical Businesses segments. The Contract Manufacturing segment manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers, and specialized health-care providers. The Other Nutraceutical Businesses segment distributes healthful nutritional products for sale through mass market, grocery, drug, and vitamin retailers under the Peaceful Sleep and Wheatgrass brands, as well as other branded proprietary nutraceutical products. This segment also sells private label vitamin and nutritional supplement products through the Internet; provides warehousing and fulfilment services; and distributes fine natural botanicals, including multi minerals, as well as raw materials. The company was formerly known as Integrated Health Technologies, Inc. Integrated BioPharma, Inc. was incorporated in 1980 and is based in Hillside, New Jersey.

Reliv' International stock logo

Reliv' International NASDAQ:RELV

Reliv' International, Inc. develops and markets nutritional supplements that address basic nutrition, specific wellness needs, weight management, and sports nutrition. The company's basic nutritional supplements are formulated to provide a balanced and complete level of supplementation for the consumer. Its principal products include Reliv Classic, Reliv Now, Innergize!, and FibRestore along with LunaRich X capsules. The company markets and sells its products through a direct selling system of independent distributors in the United States, Australia, Austria, Canada, France, Germany, Indonesia, Ireland, Malaysia, Mexico, the Netherlands, New Zealand, the Philippines, and the United Kingdom. Reliv' International, Inc. was founded in 1988 and is headquartered in Chesterfield, Missouri.